Glycogen phosphorylation and Lafora disease

被引:36
|
作者
Roach, Peter J. [1 ]
机构
[1] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA
关键词
Glycogen; Phosphorylation; Lafora disease; Laforin; Malin; PROGRESSIVE MYOCLONUS EPILEPSY; E3 UBIQUITIN LIGASE; STARCH DEGRADATION; MUSCLE GLYCOGEN; WATER DIKINASE; MALIN COMPLEX; PHOSPHATE; MICE; ACCUMULATION; METABOLISM;
D O I
10.1016/j.mam.2015.08.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Covalent phosphorylation of glycogen, first described 35 years ago, was put on firm ground through the work of the Whelan laboratory in the 1990s. But glycogen phosphorylation lay fallow until interest was rekindled in the mid 2000s by the finding that it could be removed by a glycogen-binding phosphatase, laforin, and that mutations in laforin cause a fatal teenage-onset epilepsy, called Lafora disease. Glycogen phosphorylation is due to phosphomonoesters at C2, C3 and C6 of glucose residues. Phosphate is rare, ranging from 1:500 to 1:5000 phosphates/glucose depending on the glycogen source. The mechanisms of glycogen phosphorylation remain under investigation but one hypothesis to explain C2 and perhaps C3 phosphate is that it results from a rare side reaction of the normal synthetic enzyme glycogen synthase. Lafora disease is likely caused by over-accumulation of abnormal glycogen in insoluble deposits termed Lafora bodies in neurons. The abnormality in the glycogen correlates with elevated phosphorylation (at C2, C3 and C6), reduced branching, insolubility and an enhanced tendency to aggregate and become insoluble. Hyperphosphorylation of glycogen is emerging as an important feature of this deadly childhood disease (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:78 / 84
页数:7
相关论文
共 50 条
  • [41] Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy
    Mitra, Sharmistha
    Chen, Baozhi
    Wang, Peixiang
    Chown, Erin E.
    Dear, Mathew
    Guisso, Dikran R.
    Mariam, Ummay
    Wu, Jun
    Gumusgoz, Emrah
    Minassian, Berge A.
    DISEASE MODELS & MECHANISMS, 2023, 16 (01)
  • [42] PHOSPHORYLATION OF GLYCOGEN IN SHOCK
    KOVACH, AGB
    TAKACS, L
    MENYHART, J
    IRANYI, M
    KALMAR, Z
    ACTA PHYSIOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1952, 3 (02): : 356 - 366
  • [43] Lafora disease: a review of the literature
    Desdentado, Lorena
    Espert, Raul
    Sanz, Pascual
    Tirapu-Ustarroz, Javier
    REVISTA DE NEUROLOGIA, 2019, 68 (02) : 66 - 74
  • [44] Lafora disease: A case report
    Manel, Y.
    Besma, A.
    Issam, M.
    Aida, K.
    Imen, H.
    Nada, M.
    Fethi, B.
    Ammar, B.
    VIRCHOWS ARCHIV, 2015, 467 : S207 - S207
  • [45] Phosphorylation of glycogen in vitro
    Hassid, WZ
    Chaikoff, IL
    SCIENCE, 1938, 88 : 15 - 16
  • [46] LAFORA BODY DEGRADATION BY A THERAPEUTIC ENZYME FOR THE TREATMENT OF LAFORA DISEASE
    Brewer, M. K.
    McCarthy, J.
    Pauly, J.
    McKnight, T.
    Armstrong, D.
    Gentry, M. S.
    EPILEPSIA, 2017, 58 : S166 - S166
  • [47] Retinal manifestations of Lafora disease
    Heitkotter, Heather
    Linderman, Rachel E.
    Cava, Jenna
    Woertz, Erica N.
    Mastey, Rebecca
    Summerfelt, Phyllis
    Chui, Toco Yuen Ping
    Rosen, Richard B.
    Patterson, Emily J.
    Vincent, Ajoy
    Carroll, Joseph
    Minassian, Berge A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [48] Gene therapy for Lafora disease
    Zafra-Puerta, Luis
    Iglesias-Cabeza, Nerea
    Burgos, Daniel F.
    Sciaccaluga, Miriam
    Gonzalez-Fernandez, Juan
    Bellingacci, Laura
    Canonichesi, Jacopo
    Sanchez-Martin, Gema
    Costa, Cinzia
    Sanchez, Marina P.
    Serratosa, Jose M.
    MOLECULAR THERAPY, 2024, 32 (07) : 2130 - 2149
  • [49] Pathologic Confirmation of Lafora Disease
    Rhouda, Hajar
    Malihy, Abderrahmane
    Zouiri, Ghizlane
    Kriouile, Yamna
    PEDIATRIC NEUROLOGY, 2020, 108
  • [50] Lafora Disease: Molecular Etiology
    Caglayan, S. Hande
    EPILEPSI, 2018, 24 (01): : 1 - 7